...
首页> 外文期刊>Expert opinion on biological therapy >MicroRNAs as targets for antisense-based therapeutics.
【24h】

MicroRNAs as targets for antisense-based therapeutics.

机译:MicroRNA作为基于反义疗法的靶标。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

MicroRNAs (miRNAs) are a novel class of endogenous non-coding single-stranded RNAs, which regulate gene expression post-transcriptionally by base pairing with their target mRNAs. So far > 5000 miRNA entries have been registered and miRNAs have been implicated in most, if not all, central cellular processes and several diseases. As the mechanism of action for miRNA regulation of target mRNAs is mediated by Watson-Crick base pairing, antisense oligonucleotides targeting the miRNAs appear as an obvious choice to specifically inhibit miRNA function. Indeed, miRNAs can be antagonized in vivo by oligonucleotides composed of high-affinity nucleotide mimics. Lessons learned from traditional antisense strategies and small-interfering RNA approaches, that is from potent nucleotide mimics, design rules, pharmacokinetics, administration and safety issues, are likely to pave the way for future clinical trials of miRNA-antagonizing oligonucleotides.
机译:MicroRNA(miRNA)是一类新型的内源性非编码单链RNA,它们通过与靶标mRNA碱基配对而在转录后调节基因表达。迄今为止,已经注册了超过5000个miRNA条目,并且miRNA与大多数(如果不是全部)中央细胞过程和几种疾病有关。由于通过Watson-Crick碱基配对来介导调节靶mRNA的miRNA的作用机制,靶向miRNA的反义寡核苷酸似乎是特异性抑制miRNA功能的明显选择。实际上,miRNA可以被高亲和力核苷酸模拟物组成的寡核苷酸在体内拮抗。从传统的反义策略和小干扰RNA方法(即有效的核苷酸模拟物,设计规则,药代动力学,给药和安全性问题)中吸取的经验教训可能为miRNA拮抗性寡核苷酸的未来临床试验铺平了道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号